Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy

Závadová, Eva; Vočka, Michal; Špaček, Jan; Konopásek, Bohuslav; Fucíková, T; Petruželka, Luboš

doi:10.4149/neo_2014_013

Cited by 10 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, it has been shown that VEGF is increased in plasmacytomas . Recently, it has been demonstrated that the levels of VEGF were increased in breast cancer patients resistant to hormone therapy, and this correlated inversely with the levels of serum immunoglobulins , indicating that there is probably a relation between VEGF levels, angiogenesis and impairment of humoral immunity. All the aforementioned data support our finding that immunoparesis may accompany solitary plasma cell tumors and, therefore, it could be a useful parameter for predicting evolution to MM.…”

Section: Discussionmentioning

confidence: 94%

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Katodritou¹,

Terpos

Symeonidis

et al. 2014

American J Hematol

View full text Add to dashboard Cite

Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice is local radiotherapy (R/T) 6 surgical excision. The role of adjuvant chemotherapy (C/T) or novel agents (NA) is uncertain. Data related to prognostic factors are inconclusive. Herein, we describe the clinical features, survival and prognosis of 97 consecutive patients, 65 with bone SP (SBP), and 32 with extramedullary SP (SEP), diagnosed and treated in 12 Greek Myeloma Centers. Objective response rate (PR) and complete response (CR) was 91.8% and 61.9%, respectively, and did not differ between the 2 groups. Overall, 38 patients relapsed or progressed to multiple myeloma (MM). After a median follow-up of 60 months, 5 and 10-year overall survival (OS) probability was 92% and 89% in SEP and 86% and 69% in SBP, respectively (P 5 0.2). The 5-and 10-year MMfree survival (MMFS) probability was 90% and 70% for patients with SEP vs. 59% and 50% for patients with SBP, respectively (P 5 0.054). Overall, the 5-and 10-year OS probability, plasmacytoma relapse-free survival (PRFS), progression-free survival and MMFS was 84% and 78%, 72% and 58%, 58% and 43%, and 70% and 59%, respectively. In the multivariate analysis, prolonged PRFS and young age were positive predictors of OS. Achievement of CR was the only positive predictor of PRFS. Immunoparesis was the only negative predictor of progression to MM. The addition of C/T or NA-based treatment increased toxicity without offering any survival advantage over R/T.

show abstract

Section: Discussionmentioning

confidence: 94%

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Katodritou¹,

Terpos

Symeonidis

et al. 2014

American J Hematol

View full text Add to dashboard Cite

show abstract

“…It is still unclear how immune response genes are regulated in ER+ breast cancer cells and tumors. In breast cancer patients, depression in cellular immunity was associated with resistance to endocrine therapy [ 25 ]. In vivo models of mammary tumors suggest a role of immune-associated genes in antiestrogen resistance [ 26 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer

et al. 2017

View full text Add to dashboard Cite

About 70% of all breast cancers are estrogen receptor alpha positive (ER+; ESR1). Many are treated with antiestrogens. Unfortunately, de novo and acquired resistance to antiestrogens is common but the underlying mechanisms remain unclear. Since growth of cancer cells is dependent on adequate energy and metabolites, the metabolomic profile of endocrine resistant breast cancers likely contains features that are deterministic of cell fate. Thus, we integrated data from metabolomic and transcriptomic analyses of ER+ MCF7-derived breast cancer cells that are antiestrogen sensitive (LCC1) or resistant (LCC9) that resulted in a gene-metabolite network associated with EGR1 (early growth response 1). In human ER+ breast tumors treated with endocrine therapy, higher EGR1 expression was associated with a more favorable prognosis. Mechanistic studies showed that knockdown of EGR1 inhibited cell growth in both cells and EGR1 overexpression did not affect antiestrogen sensitivity. Comparing metabolite profiles in LCC9 cells following perturbation of EGR1 showed interruption of lipid metabolism. Tolfenamic acid, an anti-inflammatory drug, decreased EGR1 protein levels and synergized with antiestrogens in inhibiting cell proliferation in LCC9 cells. Collectively, these findings indicate that EGR1 is an important regulator of breast cancer cell metabolism and is a promising target to prevent or reverse endocrine resistance.

show abstract

“…However, TGF-β inhibits sphere-forming efficiency in MCF7 cells [ 65 ]. Treatment with TGF-β increases ALDH + and CD24 low /CD44 + CSC-enriched population in breast cancer cell lines [ 66 ] The plasma levels of TGF-β are upregulated in the group of these patients with endocrine-resistant breast cancer, as compare with the healthy group [ 67 ]. High PI3K and Hh pathway activity is relative to shorter PFS of metastases during tamoxifen treatment, and high TGF-β and PI3K pathway activity with worse response in treatment [ 68 ].…”

Section: Mechanism Of Endocrine Resistance In Breast Carcinomamentioning

confidence: 99%

Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

et al. 2021

View full text Add to dashboard Cite

Drug resistance is always a great obstacle in any endocrine therapy of breast cancer. Although the combination of endocrine therapy and targeted therapy has been shown to significantly improve prognosis, refractory endocrine resistance is still common. Dysregulation of the Hippo pathway is often related to the occurrence and the development of many tumors. Targeted therapies of this pathway have played important roles in the study of triple negative breast cancer (TNBC). Targeting the Hippo pathway in combination with chemotherapy or other targeted therapies has been shown to significantly improve specific antitumor effects and reduce cancer antidrug resistance. Further exploration has shown that the Hippo pathway is closely related to endocrine resistance, and it plays a “co-correlation point” role in numerous pathways involving endocrine resistance, including related pathways in breast cancer stem cells (BCSCs). Agents and miRNAs targeting the components of the Hippo pathway are expected to significantly enhance the sensitivity of breast cancer cells to endocrine therapy. This review initially explains the possible mechanism of the Hippo pathway in combating endocrine resistance, and it concludes by recommending endocrine therapy in combination with therapies targeting the Hippo pathway in the study of endocrine-resistant breast cancers.

show abstract

Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy

Cited by 10 publications

References 39 publications

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients

EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer

Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer

Contact Info

Product

Resources

About